Auto-immune anti-N-methyl-D-aspartate receptor encephalitis: A two-case report

AIMS: To report two cases with different presentations of anti-N-methyl-D-aspartate receptor (anti-NMDAR) encephalitis, a newly identified autoimmune disease characterized by consciousness changes, memory deficit, seizures, autonomic dysfunction and movement disorders.CASES DESCRIPTION: A six-year-o...

ver descrição completa

Detalhes bibliográficos
Autores: Ferreira, Jorge André Soares Abreu, Peixoto, Sara Cecilia Carneiro, Carrilho, Inês Conceição Cancelo, Martins, Vânia Sofia Vicente
Tipo de documento: artigo
Estado:Versão publicada
Data de publicação:2018
País:Brasil
Recursos:Pontifícia Universidade Católica do Rio Grande do Sul (PUCRS)
Repositório:Scientia Medica (Porto Alegre. Online)
Idioma:português
OAI Identifier:oai:ojs.revistaseletronicas.pucrs.br:article/29534
Acesso em linha:https://revistaseletronicas.pucrs.br/scientiamedica/article/view/29534
Access Level:Acceso aberto
Palavra-chave:encephalitis
anti-N-methyl-D-aspartate receptor encephalitis
anti-NMDA receptor encephalitis
seizures
movement disorders.
encefalite
encefalite antirreceptor N-metil-D-aspartato
encefalite antirreceptor NMDA
convulsões
distúrbios do movimento.
Descrição
Resumo:AIMS: To report two cases with different presentations of anti-N-methyl-D-aspartate receptor (anti-NMDAR) encephalitis, a newly identified autoimmune disease characterized by consciousness changes, memory deficit, seizures, autonomic dysfunction and movement disorders.CASES DESCRIPTION: A six-year-old female, who presented with dystonic and choreoathetoid movements with refusal to walk. A 17-year-old male, presented with behavioral changes, retrograde amnesia and seizures. Electroencephalogram and brain magnetic resonance imaging did not show any significant findings. Anti-NMDAR antibodies were positive in cerebrospinal fluid in both cases and in serum in the first patient. Methylprednisolone, immunoglobulin and rituximab were given at different intervals. Both had a recurrence about six months later, with recovery at the end of one and a half year of the diagnosis.CONCLUSIONS: Anti-NMDAR encephalitis should be considered in patients with sudden onset of neuropsychiatric symptoms. Early diagnosis and treatment are major prognostic factors.